UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 6-K
 

 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of: January 2017
 

 
Commission File Number: 001- 37413
 

 
Concordia International Corp.
(Translation of registrant’s name into English)
 

 
277 Lakeshore Road East, Suite 302
Oakville, Ontario
L6J 1H9
(Address of principal executive offices)
 

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F o Form 40-F x
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
 
 
 





 
On January 3, 2017, Concordia International Corp. (the “Corporation”) today announced it has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) through which the companies expect to expand sales of Donnatal®, the Corporation’s product used in treatment of irritable bowel syndrome. In conjunction with this report the Corporation is filing the following exhibit:
Exhibit 99.1        Press release of Concordia International Corp. dated January 3, 2017.
    








SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
Concordia International Corp.
 
 
 
 
 
 
 
 
 
 
By:
 
/s/ Edward Borkowski
 
 
 
 
Name:
 
Edward Borkowski
 
 
 
 
 
Title:
 
Chief Financial Officer
 
 
 
Date: January 3, 2017





 
EXHIBIT INDEX

  Exhibit  
No.
 
Description
 
 
 
99.1
 
Press release of Concordia International Corp. dated January 3, 2017.